

CADTH REIMBURSEMENT REVIEW

Stakeholder Feedback on Draft Recommendation

Empagliflozin (Jardiance)
(Boehringer Ingelheim (Canada) Ltd.)

Indication: Heart failure.

September 29, 2022

Disclaimer: The views expressed in this submission are those of the submitting organization or individual. As such, they are independent of CADTH and do not necessarily represent or reflect the view of CADTH. No endorsement by CADTH is intended or should be inferred.

By filing with CADTH, the submitting organization or individual agrees to the full disclosure of the information. CADTH does not edit the content of the submissions.

CADTH does use reasonable care to prevent disclosure of personal information in posted material; however, it is ultimately the submitter's responsibility to ensure no identifying personal information or personal health information is included in the submission. The name of the submitting stakeholder group and all conflicts of interest information from individuals who contributed to the content are included in the posted submission.

CADTH Reimbursement Review

Feedback on Draft Recommendation

Stakeholder information		
CADTH project number	SR0726	
Name of the drug and Indication(s)	Empagliflozin (Jardiance) indicated in adults, as an adjunct to standard of care therapy for the treatment of chronic heart failure	
Organization Providing Feedback	FWG	
1. Recommendation revisions		
Please indicate if the stakeholder requires the expert review committee to reconsider or clarify its recommendation.		
Request for Reconsideration	Major revisions: A change in recommendation category or patient population is requested	<input type="checkbox"/>
	Minor revisions: A change in reimbursement conditions is requested	<input type="checkbox"/>
No Request for Reconsideration	Editorial revisions: Clarifications in recommendation text are requested	<input checked="" type="checkbox"/>
	No requested revisions	<input type="checkbox"/>
2. Change in recommendation category or conditions		
Complete this section if major or minor revisions are requested		
Please identify the specific text from the recommendation and provide a rationale for requesting a change in recommendation.		
3. Clarity of the recommendation		
Complete this section if editorial revisions are requested for the following elements		
a) Recommendation rationale		
<ol style="list-style-type: none"> 1) Please clarify the cost condition, in that the incremental cost is related to jardiance alone, as standard of therapy is currently funded. 2) It would be helpful if the requirement for patients to be on standard therapies of BB+ACE/ARB/ARNI+MRA was included in the reimbursement conditions. 3) Further clarity around the price comparison between empagliflozin and dapagliflozin should be provided, potentially in a discussion point, as the empagliflozin is broader and includes patients with both preserved and reduced ejection fraction. Please provide details regarding the information that requires clarification. 		

b) Reimbursement conditions and related reasons
Please provide details regarding the information that requires clarification.
c) Implementation guidance
Please provide high-level details regarding the information that requires clarification. You can provide specific comments in the draft recommendation found in the next section. Additional implementation questions can be raised here.